We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+16.38%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.76B
AUM Growth
+$415M
(+12%)
Cap. Flow
+$232M
Cap. Flow
% of AUM
6.17%
Top 10 Holdings %
Top 10 Hldgs %
70.32%
Holding
347
New
79
Increased
17
Reduced
40
Closed
111
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DAY
Dayforce
DAY
|
+$282M |
| 2 |
CMA
Comerica
CMA
|
+$267M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$240M |
| 4 |
HOLX
Hologic
HOLX
|
+$190M |
| 5 |
EXAS
Exact Sciences
EXAS
|
+$143M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRNA
Verona Pharma
VRNA
|
+$457M |
| 2 |
K
Kellanova
K
|
+$290M |
| 3 |
COOP
Mr. Cooper
COOP
|
+$169M |
| 4 |
IPG
Interpublic Group of Companies
IPG
|
+$132M |
| 5 |
INFA
Informatica
INFA
|
+$113M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.61% |
| 2 | Healthcare | 19.41% |
| 3 | Industrials | 18.06% |
| 4 | Financials | 17.96% |
| 5 | Communication Services | 7.48% |
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q4 2025 Portfolio in Review
As of Q4 2025, UBS O'Connor held 347 positions worth $3.76B, up 12% from $3.34B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
UBS O'Connor deployed $232M of net new capital in Q4 2025, opening 79 new positions and adding to 17 existing holdings. Its largest new stake was Dayforce: 4,096,708 shares worth $283M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 22% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was NVIDIA, an estimated $17M trimmed.
- UBS O'Connor's largest Q4 2025 buy was Dayforce: 4,096,708 shares worth $283M.
- UBS O'Connor added most to Air Lease Corp in Q4 2025, an estimated $142M increase.
- UBS O'Connor's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $17M.
- UBS O'Connor fully exited Verona Pharma in Q4 2025, selling an estimated $457M.
- UBS O'Connor's ten largest holdings make up 70% of its $3.76B portfolio in Q4 2025.
- UBS O'Connor opened 79 new positions and closed 111 in Q4 2025.
- UBS O'Connor's portfolio value rose 12% quarter-over-quarter to $3.76B.
Based on UBS O'Connor's 13F filing for Q4 2025, filed 13 Feb 2026.